Drug-Eluting Biodegradable Implants for the Sustained Release of <i>Bis</i>phosphonates
Despite being one of the first-line treatments for osteoporosis, the <i>bis</i>phosphonate drug class exhibits an extremely low oral bioavailability (<1%) due to poor absorption from the gastrointestinal tract. To overcome this, and to explore the potential for sustained drug release,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Polymers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4360/12/12/2930 |